AI-generated summaries. Verify every claim with the cited sources before acting on them. Read our methodology

← Back to all reports

CHARGE Syndrome

Recent research efforts aimed at curing CHARGE Syndrome.

Last updated
Also available in
Français — Syndrome CHARGE

CHARGE Syndrome

Overview

CHARGE syndrome is a rare, usually sporadic genetic developmental condition that affects many parts of the body. It is most often caused by a harmful change in one copy of CHD7, a gene that helps organize chromatin—the packaging around DNA that controls when other genes are active during early development. “CHARGE” refers to commonly associated features: coloboma of the eye, heart defects, choanal atresia or narrowing of the nasal airway, growth and developmental differences, genital differences, and ear abnormalities including hearing loss; cranial-nerve, balance, feeding, kidney, brain, and endocrine problems are also frequent. CHD7 Disorder (ncbi.nlm.nih.gov)

Severity varies substantially. Early mortality can be high when complex heart defects, airway problems, and feeding difficulties are severe, but many people with CHARGE syndrome live into adulthood and can have normal life expectancy. There is currently no cure or disease-modifying treatment. Standard care is individualized, multidisciplinary management: repair of structural problems when appropriate; airway, cardiac, feeding, endocrine, hearing, vision, balance, developmental, communication, and educational support; and lifelong surveillance for complications. CHD7 Disorder (ncbi.nlm.nih.gov)

Scope of Recent Research (2020–present)

Research from 2020 through September 11, 2026 has been scientifically active but remains predominantly preclinical. The central questions are which developmental cells and gene networks are most vulnerable to reduced CHD7 activity, whether downstream pathways can be safely corrected after birth, and whether increasing output from the remaining intact CHD7 copy could help selected features. The field is not close to a whole-body curative therapy: a 2025 analysis found that nearly all identified U.S. NIH investment in CHARGE research through 2024 was basic, early-stage research rather than clinical translation. NIH funding analysis (pmc.ncbi.nlm.nih.gov)

Major Breakthroughs and Emerging Therapies

Small molecules and pathway correction. A 2021 study used CHD7-deficient zebrafish and Caenorhabditis elegans models to identify disrupted MAPK/ERK signaling—a cell-communication pathway—as a contributor to altered inhibitory GABA-producing neurons and hyperactivity-like behavior. In those models, ephedrine normalized ERK signaling and improved the measured neuronal and behavioral abnormalities. This was an important proof of principle that some consequences of CHD7 loss may be pharmacologically modifiable, but it was not a human study and did not repair CHD7 or reverse congenital malformations. Ephedrine’s cardiovascular and neurologic effects make safety, dose, timing, and more selective derivatives essential before any clinical consideration. CHD7–PAQR3–ERK study (pmc.ncbi.nlm.nih.gov)

RNA-based gene-upregulation concepts. The CHARGE Syndrome Foundation funded a 2024 project called “SINEUP for CHARGE,” led by Albert Basson and Stefano Espinoza. SINEUPs are RNA molecules designed to increase protein production from a selected messenger RNA; in principle, this could raise production from a person’s remaining functional CHD7 allele without changing DNA. This is a plausible strategy for CHD7 haploinsufficiency—having too little protein from one working copy—but it remains an early research effort, with no public CHARGE-specific preclinical efficacy results or human trial results reported. Foundation grant archive (chargesyndrome.org)

Human stem-cell and organoid models. In 2022, researchers created human inner-ear organoids from pluripotent stem cells with CHD7 loss or a patient-associated CHD7 variant. CHD7-deficient organoids failed to generate hair cells and supporting cells, while mixed “chimeric” organoids containing both unaffected and CHD7-deficient cells partly restored expression of key inner-ear developmental genes. The partial molecular rescue is encouraging because it suggests that local signals or downstream factors may be therapeutically useful; however, it did not restore hair-cell formation in the CHD7-deficient cells and is not a cell therapy ready for patients. Human inner-ear organoids (nature.com)

Gene regulation, gene editing, and target discovery. A 2024 study mapped previously unrecognized DNA enhancer elements that control Chd7 expression in neural-crest cells, the embryonic cell population relevant to many CHARGE features. In 2026, a zebrafish multi-omics study combined RNA and protein measurements and used CRISPR/Cas9 knockdown to validate three downstream candidate genes that can reproduce CHD7-related behavioral defects. These studies do not constitute therapeutic gene editing; rather, they provide a map of possible targets, biomarkers, cell types, and developmental windows for future precision medicines. Neural-crest CHD7 enhancers Zebrafish multi-omics (journals.plos.org)

Clinical Trials and Experimental Approaches

As of September 11, 2026, no registered interventional clinical trial testing a CHARGE-specific disease-modifying, gene-replacement, gene-editing, RNA, or cell therapy was identified. The principal CHARGE-specific ClinicalTrials.gov record, NCT03186144, was a completed, non-therapeutic French clinical and molecular cohort study sponsored by Poitiers University Hospital. It enrolled 141 participants and used blood collection and genetic analysis to study phenotype–genotype relationships; its phase was “not applicable,” and no treatment outcomes were posted. NCT03186144 (clinicaltrials.gov)

CHARGE syndrome is included among conditions in the ongoing FACE-Rare supportive-care study, NCT06938542, sponsored by Children’s National Research Institute with collaborators including NICHD, Stanford University, and Akron Children’s Hospital. This phase-not-applicable study is evaluating a family-centered pediatric palliative-care intervention and caregiver outcomes, not a biological treatment for CHARGE syndrome; it therefore may improve support and care planning but is not a curative trial. NCT06938542 (clinicaltrials.gov)

Methodologies and Scientific Approaches

Researchers are combining animal models with human developmental systems. Zebrafish enable rapid whole-organism genetic and drug screens, including behavioral assays and CRISPR testing of suspected downstream genes. Mouse models allow investigators to examine tissue-specific and time-specific CHD7 requirements in organs such as the brain and inner ear, while human pluripotent-stem-cell organoids model otherwise inaccessible stages of fetal development in a human genetic context. Zebrafish multi-omics Human inner-ear organoids (pubmed.ncbi.nlm.nih.gov)

The field increasingly uses epigenomics and multi-omics: ATAC-seq to identify open, potentially active DNA regions; chromatin and enhancer mapping to find the switches controlling CHD7; RNA sequencing to measure altered gene activity; and proteomics to measure protein-level effects. These platforms are being used to identify biomarkers and smaller downstream targets that may be easier to modulate than CHD7 itself. Neural-crest CHD7 enhancers Zebrafish multi-omics (journals.plos.org)

Leading Institutions and Funding

Key contributors include the University of Michigan, North Carolina State University, Indiana University, the Stowers Institute for Medical Research, the University of Oxford, the German Cancer Research Center, the University of Exeter, the University of Milan, Radboud University, INRS, and Université du Québec à Montréal. Recent work spans neural-crest enhancer biology, inner-ear organoids, zebrafish chemical screening, brain-development models, and CHD7 overexpression concepts. Neural-crest CHD7 enhancers Human inner-ear organoids Foundation grant archive (journals.plos.org)

The CHARGE Syndrome Foundation provides peer-reviewed grants of up to $50,000 and reports that its grantees have subsequently secured nearly $12 million from NIH and other government agencies. Across 45 CHARGE-related projects from 2000 through 2024, NIH funding totaled about $64.3 million; the largest identified institute-level contributions came from the National Eye Institute and National Institute on Deafness and Other Communication Disorders, but virtually all funding was categorized as basic research. Foundation-supported research NIH funding analysis (chargesyndrome.org)

Strengths, Limitations, and Challenges

A major strength is that CHARGE syndrome has a well-established principal genetic cause and increasingly sophisticated models that reproduce specific aspects of the condition. The recent ability to connect CHD7 loss to particular downstream pathways, enhancer elements, cell types, and measurable phenotypes makes rational treatment design more feasible than simply screening drugs without a mechanism. CHD7–PAQR3–ERK study Neural-crest CHD7 enhancers Zebrafish multi-omics (pmc.ncbi.nlm.nih.gov)

The central limitation is biological timing. CHD7 acts broadly during embryo development, and many CHARGE features are structural differences present at birth; restoring gene activity later may not reconstruct an absent semicircular canal, repair a complex heart defect, or replace missing sensory cells. Any strategy that raises CHD7 must also establish the correct dose, tissues, developmental timing, and long-term safety, because CHD7 regulates many genes across the body. Small-molecule findings in fish or worms, partial molecular rescue in organoids, and genetic target validation are valuable steps, but none yet demonstrate benefit in people with CHARGE syndrome. Human inner-ear organoids NIH funding analysis (nature.com)

Outlook and Future Directions

A cure for established, multisystem CHARGE syndrome is not imminent as of September 11, 2026. The most credible nearer-term path is likely feature-specific treatment—such as improving selected neurobehavioral, hearing-related, or developmental outcomes—rather than reversal of all congenital anomalies. Milestones to watch are publication of results from CHD7-upregulation approaches such as SINEUPs; replication of pathway-correcting compounds in mammalian and human models; demonstration that treatment after birth produces durable functional benefit; validated biomarkers and natural-history cohorts suitable for trials; and the first CHARGE-specific disease-modifying clinical trial. Foundation grant archive NIH funding analysis (chargesyndrome.org)

References

Don't see your disease? Request a report